🇺🇸 FDA
Patent

US 10351589

3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

granted A61KA61K31/57A61K45/06

Quick answer

US patent 10351589 (3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders) held by Umecrine Cognition AB expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Umecrine Cognition AB
Grant date
Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/57, A61K45/06, A61P, A61P1/16